RAPP

Rapport Therapeutics, Inc.

26.51 USD
+0.36 (+1.38%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Rapport Therapeutics, Inc. stock is up 4.87% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 1 July’s closed higher than June. 100% of analysts rate it a buy.

About Rapport Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (“CNS”) disorders. We were incorporated under the laws of the State of Delaware in February 2022 under the name Precision Neuroscience NewCo, Inc., and changed our name to Rapport Therapeutics, Inc. in October 2022. Our principal executive offices are located at 1325 Boylston Street, Suite 401, Boston, MA. We have one subsidiary, Rapport Therapeutics Securities Corporation, formed in December 2022 under the laws of the Commonwealth of Massachusetts.

  • TD Cowen
    Tue Jul 2, 10:10
    buy
    initial
  • Jefferies
    Tue Jul 2, 08:03
    buy
    initial
  • Stifel
    Tue Jul 2, 05:53
    buy
    initial